GSK
About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Employees: 68,629
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
339% more call options, than puts
Call options by funds: $460M | Put options by funds: $105M
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
0.76% more ownership
Funds ownership: 7.48% [Q3] → 8.24% (+0.76%) [Q4]
6% less funds holding
Funds holding: 888 [Q3] → 831 (-57) [Q4]
9% less capital invested
Capital invested by funds: $12.6B [Q3] → $11.6B (-$1.08B) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 282 | Existing positions reduced: 318
30% less first-time investments, than exits
New positions opened: 104 | Existing positions closed: 148
Research analyst outlook
We haven’t received any recent analyst ratings for GSK.
Financial journalist opinion
Based on 258 articles about GSK published over the past 30 days
Negative
CNBC
4 hours ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Negative
Proactive Investors
1 day ago
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that
UBS has warned that drugmakers such as AstraZeneca and GSK could be among the most exposed in Europe's pharmaceuticals sector should President Trump follow through on threats to impose new levies on the industry, despite medicine currently being exempt from trade tariffs. In a detailed report analysing potential flashpoints for investors, the Swiss bank argues that while the European sector as a whole remains a defensive play in a possible global downturn, key companies could face pressure from changes to US tax policy and regulatory disruption.
Positive
CNBC
1 day ago
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a "lack of respect.
Neutral
CNBC Television
1 day ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Negative
Seeking Alpha
1 day ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
Negative
Reuters
2 days ago
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.
Negative
CNBC
2 days ago
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Negative
WSJ
2 days ago
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Negative
CNBC
2 days ago
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Neutral
Business Wire
2 days ago
GSK Awards $2M in Grant Funding for Programs Supporting Adult Vaccination, Commits Additional $2M for 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK awards $2M in grant funding for programs supporting adult vaccination, commits additional $2M for 2025.
Charts implemented using Lightweight Charts™